Did you know that the Mirasol Pathogen Reduction Technology (PRT) offered by Sudabelt Medical’s partner Terumo Blood Cell Technology, can inactivate both enveloped and non-enveloped viruses in blood samples? This innovative technology is transforming the safety of blood transfusions and plasma-derived products, significantly reducing the risk of viral transmission.
How Does Mirasol PRT Work?
Mirasol PRT uses a combination of riboflavin (vitamin B2) and ultraviolet (UV) light to target and inactivate pathogens in blood components. The process works by binding riboflavin to nucleic acids (DNA and RNA) in viruses, bacteria, and other pathogens. When exposed to UV light, the riboflavin induces irreversible damage to the nucleic acids, preventing the pathogens from replicating and rendering them non-infectious.
Enveloped vs. Non-Enveloped Viruses
Viruses are categorized into two types based on their structure:
- Enveloped viruses: These viruses have a lipid membrane surrounding their genetic material. Examples include HIV, hepatitis B (HBV), and influenza.
- Non-enveloped viruses: These lack a lipid membrane and are generally more resistant to disinfectants. Examples include hepatitis A (HAV) and parvovirus B19.
Mirasol PRT is effective against both types of viruses, making it a comprehensive solution for blood safety.
Benefits of Mirasol PRT
- Enhanced Blood Safety: Reduces the risk of transmitting infectious agents through blood transfusions.
- Broad-Spectrum Efficacy: Effective against a wide range of pathogens, including bacteria, viruses, and protozoa.
- Preservation of Blood Quality: The process does not significantly alter the functional properties of blood components, ensuring they remain safe for clinical use.
The Mirasol Pathogen Reduction Technology represents a significant advancement in blood transfusion safety. By inactivating both enveloped and non-enveloped viruses, it provides an extra layer of protection for patients and healthcare providers, reducing the risk of transfusion-transmitted infections and enhancing the overall safety of blood products.
References
- Allain, J.P., et al., Prevention of Transfusion-Transmitted Malaria by Treatment of Whole Blood with the Mirasol PRT System, Blood, 2015.
- Custer, B., et al., The Cost-Effectiveness of Pathogen Reduction Technology as Assessed Using a Multiple Risk Reduction Model, Transfusion, 2010.
- Goodrich, R.P., The Antiviral and Antibacterial Properties of Riboflavin and Light: Applications to Blood Safety and Transfusion Medicine, Royal Society of Chemistry, 2006.
- Mundt, J.M., et al., Chemical and Biological Mechanisms of Pathogen Reduction Technologies, Photochemistry and Photobiology, 2014.
- Reddy, H.L., et al., Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation, Transfusion Medicine Reviews, 2008.
- Terumo BCT, Mirasol Pathogen Reduction Technology Overview, Terumo BCT Website.
- Frontiers in Medicine, Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine, 2021.
